The post Solana price slips – Yet $60M ETF inflows hint at SOL rebound appeared on BitcoinEthereumNews.com. Journalist Posted: November 15, 2025 Key takeaways Is institutional demand for Solana still holding up? SOL ETFs logged multiple inflow peaks above $60 million, keeping total assets near $541 million. Are derivatives traders ready for a rebound? OI stayed firm near $2.95 billion, and Funding Rates flipped positive. Solana [SOL] is back at levels not seen since June, but the market mood isn’t as bleak as the charts show. Institutional inflows are steady, and derivatives data is starting to show a slight change. Are traders preparing for what comes next? ETF demand stays firm Solana ETFs continue to record steady inflows even as spot prices fall to multi-month lows. Daily net inflows have remained positive across most sessions, with peaks above $60 million on 28th October and 3rd November. Total net assets were around $541 million at press time; there’s no meaningful investor walkout. Source: SoSoValue While inflows have thinned in recent days, they have not reversed, and cumulative demand has held up through the broader market drop. Large investors are still committed to the asset. AMBCrypto previously reported that VanEck has filed an 8-A form with the SEC, so its long-awaited Solana spot ETF may be nearing launch, too. Momentum turns That strength from ETF flows contrasts with SOL’s weekly chart, where price momentum continues to deteriorate. The altcoin dropped below the 50-week EMA at $176 and tested the 100-week EMA near $157, a level it last went around in June. Selling volume has increased for two consecutive weeks, so there’s sustained pressure. Source: TradingView At press time, the RSI neared oversold territory, while MACD extended its bearish crossover with deeper red bars appearing. The broader trend remains downward, and SOL will need to reclaim the mid-$150s to stabilize its longer-term structure. Steadier derivatives numbers Building on that, derivatives… The post Solana price slips – Yet $60M ETF inflows hint at SOL rebound appeared on BitcoinEthereumNews.com. Journalist Posted: November 15, 2025 Key takeaways Is institutional demand for Solana still holding up? SOL ETFs logged multiple inflow peaks above $60 million, keeping total assets near $541 million. Are derivatives traders ready for a rebound? OI stayed firm near $2.95 billion, and Funding Rates flipped positive. Solana [SOL] is back at levels not seen since June, but the market mood isn’t as bleak as the charts show. Institutional inflows are steady, and derivatives data is starting to show a slight change. Are traders preparing for what comes next? ETF demand stays firm Solana ETFs continue to record steady inflows even as spot prices fall to multi-month lows. Daily net inflows have remained positive across most sessions, with peaks above $60 million on 28th October and 3rd November. Total net assets were around $541 million at press time; there’s no meaningful investor walkout. Source: SoSoValue While inflows have thinned in recent days, they have not reversed, and cumulative demand has held up through the broader market drop. Large investors are still committed to the asset. AMBCrypto previously reported that VanEck has filed an 8-A form with the SEC, so its long-awaited Solana spot ETF may be nearing launch, too. Momentum turns That strength from ETF flows contrasts with SOL’s weekly chart, where price momentum continues to deteriorate. The altcoin dropped below the 50-week EMA at $176 and tested the 100-week EMA near $157, a level it last went around in June. Selling volume has increased for two consecutive weeks, so there’s sustained pressure. Source: TradingView At press time, the RSI neared oversold territory, while MACD extended its bearish crossover with deeper red bars appearing. The broader trend remains downward, and SOL will need to reclaim the mid-$150s to stabilize its longer-term structure. Steadier derivatives numbers Building on that, derivatives…

Solana price slips – Yet $60M ETF inflows hint at SOL rebound

Key takeaways

Is institutional demand for Solana still holding up?

SOL ETFs logged multiple inflow peaks above $60 million, keeping total assets near $541 million.

Are derivatives traders ready for a rebound?

OI stayed firm near $2.95 billion, and Funding Rates flipped positive.


Solana [SOL] is back at levels not seen since June, but the market mood isn’t as bleak as the charts show.

Institutional inflows are steady, and derivatives data is starting to show a slight change. Are traders preparing for what comes next?

ETF demand stays firm

Solana ETFs continue to record steady inflows even as spot prices fall to multi-month lows.

Daily net inflows have remained positive across most sessions, with peaks above $60 million on 28th October and 3rd November. Total net assets were around $541 million at press time; there’s no meaningful investor walkout.

Source: SoSoValue

While inflows have thinned in recent days, they have not reversed, and cumulative demand has held up through the broader market drop. Large investors are still committed to the asset.

AMBCrypto previously reported that VanEck has filed an 8-A form with the SEC, so its long-awaited Solana spot ETF may be nearing launch, too.

Momentum turns

That strength from ETF flows contrasts with SOL’s weekly chart, where price momentum continues to deteriorate.

The altcoin dropped below the 50-week EMA at $176 and tested the 100-week EMA near $157, a level it last went around in June. Selling volume has increased for two consecutive weeks, so there’s sustained pressure.

Source: TradingView

At press time, the RSI neared oversold territory, while MACD extended its bearish crossover with deeper red bars appearing. The broader trend remains downward, and SOL will need to reclaim the mid-$150s to stabilize its longer-term structure.

Steadier derivatives numbers

Building on that, derivatives data is stabilizing.

Source: Coinalyze

Aggregated Open Interest (OI) held close to the $2.94-$2.95 billion range through the week, avoiding any liquidation-driven drops even as spot prices weakened.

This steady OI means leverage was not being rapidly unwound. Funding rates, which spent most of the period in negative territory, went back above zero and printed around 0.0084 at press time.

Perhaps there’s a return of long-side positioning after days of cautiousness. Traders are beginning to re-enter rather than de-risk further.

Next: Jupiter price dips – Can $26M Q4 holder income help JUP’s recovery

Source: https://ambcrypto.com/solana-price-slips-yet-60m-etf-inflows-hint-at-sol-rebound/

Market Opportunity
Hive Intelligence Logo
Hive Intelligence Price(HINT)
$0,001919
$0,001919$0,001919
+0,52%
USD
Hive Intelligence (HINT) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Over $145M Evaporates In Brutal Long Squeeze

Over $145M Evaporates In Brutal Long Squeeze

The post Over $145M Evaporates In Brutal Long Squeeze appeared on BitcoinEthereumNews.com. Crypto Futures Liquidations: Over $145M Evaporates In Brutal Long Squeeze
Share
BitcoinEthereumNews2026/01/16 11:35
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Edges higher ahead of BoC-Fed policy outcome

Edges higher ahead of BoC-Fed policy outcome

The post Edges higher ahead of BoC-Fed policy outcome appeared on BitcoinEthereumNews.com. USD/CAD gains marginally to near 1.3760 ahead of monetary policy announcements by the Fed and the BoC. Both the Fed and the BoC are expected to lower interest rates. USD/CAD forms a Head and Shoulder chart pattern. The USD/CAD pair ticks up to near 1.3760 during the late European session on Wednesday. The Loonie pair gains marginally ahead of monetary policy outcomes by the Bank of Canada (BoC) and the Federal Reserve (Fed) during New York trading hours. Both the BoC and the Fed are expected to cut interest rates amid mounting labor market conditions in their respective economies. Inflationary pressures in the Canadian economy have cooled down, emerging as another reason behind the BoC’s dovish expectations. However, the Fed is expected to start the monetary-easing campaign despite the United States (US) inflation remaining higher. Investors will closely monitor press conferences from both Fed Chair Jerome Powell and BoC Governor Tiff Macklem to get cues about whether there will be more interest rate cuts in the remainder of the year. According to analysts from Barclays, the Fed’s latest median projections for interest rates are likely to call for three interest rate cuts by 2025. Ahead of the Fed’s monetary policy, the US Dollar Index (DXY), which tracks the Greenback’s value against six major currencies, holds onto Tuesday’s losses near 96.60. USD/CAD forms a Head and Shoulder chart pattern, which indicates a bearish reversal. The neckline of the above-mentioned chart pattern is plotted near 1.3715. The near-term trend of the pair remains bearish as it stays below the 20-day Exponential Moving Average (EMA), which trades around 1.3800. The 14-day Relative Strength Index (RSI) slides to near 40.00. A fresh bearish momentum would emerge if the RSI falls below that level. Going forward, the asset could slide towards the round level of…
Share
BitcoinEthereumNews2025/09/18 01:23